SGP Form 4 reports acquisition/exercise transactions

Pujara Chetan Pratap reported acquisition or exercise transactions in a Form 4 filing for SGP.

Rhea-AI Filing Summary

Pujara Chetan Pratap reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 105,000 shares. Following the reported transactions, holdings were 105,000 shares.

Insider Trade Summary

Grant/Award: 105,000 shares

Grant/Award 1 txn

Insider Pujara Chetan Pratap

Role Chief R&D Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	105,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 105,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SpyGlass Pharma (SGP) report for Chetan Pratap Pujara?

SpyGlass Pharma reported that Chief R&D Officer Chetan Pratap Pujara received a grant of 105,000 stock options on February 5, 2026. These options are a derivative security giving him the right to buy common stock at a fixed exercise price, subject to vesting conditions.

What are the key terms of the 105,000 stock options granted by SpyGlass Pharma (SGP)?

The grant consists of 105,000 stock options with an exercise price of $16 per share and an expiration date of February 5, 2036. The options are held directly and represent a compensation award to the company’s Chief R&D Officer, as disclosed in the Form 4 filing.

How do the SpyGlass Pharma (SGP) stock options granted on February 5, 2026 vest?

Vesting begins one year after the vesting commencement date of February 5, 2026, when 25% of the options vest. The remaining options vest in equal monthly installments of one forty-eighth of the total, contingent on the officer continuing as a service provider.

What role does the reporting person hold at SpyGlass Pharma (SGP)?

The reporting person, Chetan Pratap Pujara, serves as SpyGlass Pharma’s Chief R&D Officer. The Form 4 identifies him as an officer, not a director or 10% owner, and reports a compensatory stock option grant linked to his continued service with the company.

What is the expiration date of the SpyGlass Pharma (SGP) stock options granted to the Chief R&D Officer?

The stock options granted to the Chief R&D Officer expire on February 5, 2036. This gives a ten-year term from the February 5, 2026 grant date, during which vested options can be exercised at the specified $16 per share exercise price, subject to plan terms.

How many SpyGlass Pharma (SGP) derivative securities does the officer own after this transaction?

Following the reported transaction, the officer beneficially owns 105,000 derivative securities in the form of stock options. All of these options are reported as held directly, reflecting the full grant amount disclosed in the Form 4 after the award on February 5, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:42 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pujara Chetan Pratap

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief R&D Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		105,000		(1)	02/05/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.